With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.497-25-6,Oxazolidin-2-one,as a common compound, the synthetic route is as follows.
497-25-6, Example 40: Synthesis of 4-{(3-chloro-5-trifluoromethyl-benzyl)-[5-(2-oxo-oxazolidin- 3-yl)-pyrimidin-2-yl]-amino}-2,6-diethyl-piperidine-1 -carboxylic acid isopropyl ester; A mixture of 4-[(5-bromo-pyrimidin-2-yl)-(3-chloro-5-trifluoromethyl-benzyl)-amino]- 2,6-diethyl-piperidine-1-carboxylic acid isopropyl ester (0.05 mmol, 30 mg), oxazolidin-2-one (0.05 mmol, 5 mg), cupper iodide (0.05 mmol, 10 mg), frans-cyclohexane-1 ,2-diamine (0.05 mmol, 6 mg) and potassium carbonate (0.1 mmol, 14 mg) in 1 ,4-dioxane (0.3 ml_) is allowed to warm to 110 0C and stirred for 19 hours. The mixture is cooled to room temperature and then added aq. ammonia. The mixture is extracted with CH2CI2. The combined organic layer is washed with brine, dried over Na2SO4, filtrated, and concentrated under reduced pressure. The obtained residue is purified by silica gel column chromatography (eluent: n- hexane / EtOAc) to give 4-{(3-chloro-5-trifluoromethyl-benzyl)-[5-(2-oxo-oxazolidin-3-yl)- pyrimidin-2-yl]-amino}-2,6-diethyl-piperidine-1-carboxylic acid isopropyl ester (26 mg, 87%); ESI-MS m/z: 598 [M+1]+, Retention time 2.44 min (condition A).
As the paragraph descriping shows that 497-25-6 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2008/9435; (2008); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem